The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | The importance risk stratification to enable risk-adapted therapy in MDS & CMML
Luis Aguirre, MD, Moffitt Cancer Center, Tampa, FL, explains the importance of applying risk stratification models to optimize treatment for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
